Publications by authors named "G Parvis"
Article Synopsis
- Lymphoproliferative disorders, including lymphoma, can recur even years after treatment, so patients in remission need regular check-ups.
- There's debate over the use of imaging for these follow-ups, as traditional methods expose patients to harmful ionizing radiation, while whole-body MRI with diffusion-weighted imaging (WB-MRI-DWI) offers a radiation-free alternative.
- A study reviewing cases from 2010 to 2022 found WB-MRI-DWI highly effective for follow-ups, achieving 100% sensitivity and 98.6% specificity in detecting potential lymphoma relapses, although some false positives were noted.
The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial.
Cancer Med
December 2020
Background: The neutrophil to lymphocyte ratio (NLR) and the lymphocyte to monocyte ratio (LMR) can reflect both the myeloid dysfunction and T-cell immune suppression and have prognostic significance.
Methods: In 771 newly diagnosed advanced-stage Hodgkin Lymphoma (HL) patients we evaluated the baseline values of NLR and LMR as predictors of clinical outcome. According to the multicenter prospective phase II GITIL-HD0607 trial, all patients received two ABVD courses and if PET-2 negative received four additional ABVD cycles while if PET-2-positive patients were randomized to either BEACOPP escalated (Be) plus BEACOPP baseline (Bb) (4 + 4 courses) or Be + Bb (4 + 4) and Rituximab.
The development of drugs able to target BTK, PI3k-delta and BCL2 has dramatically improved chronic lymphocytic leukaemia (CLL) therapies. However, drug resistance to these therapies has already been reported due to non-recurrent changes in oncogenic pathways and genes expression signatures. In this study, we investigated the cooperative role of the BCL2 inhibitor venetoclax and the BRD4 inhibitor JQ1.
View Article and Find Full Text PDFArticle Synopsis
- A study looked at two types of chemotherapy for young people with a type of cancer called follicular lymphoma from 2000 to 2005, and found that both treatments worked similarly in helping patients survive.
- After 13 years, about 66% of the patients were still alive, and most deaths were because the cancer got worse or due to other health problems.
- The study showed that patients who achieved complete remission (where the cancer is no longer detectable) lived longer, and this research highlighted significant improvements in survival compared to treatments before using a medicine called rituximab.
Non-Hodgkin lymphoma (NHL) of the lip is extremely rare. It is usually indolent and in early stages a local approach is often indicated. We present a case report of a patient with extranodal NHL of the lip treated with chemotherapy and low-dose radiation treatment (RT).
View Article and Find Full Text PDF